SG11202105197UA - Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia - Google Patents
Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemiaInfo
- Publication number
- SG11202105197UA SG11202105197UA SG11202105197UA SG11202105197UA SG11202105197UA SG 11202105197U A SG11202105197U A SG 11202105197UA SG 11202105197U A SG11202105197U A SG 11202105197UA SG 11202105197U A SG11202105197U A SG 11202105197UA SG 11202105197U A SG11202105197U A SG 11202105197UA
- Authority
- SG
- Singapore
- Prior art keywords
- venetoclax
- bcl
- inhibitor
- combination therapy
- myeloid leukemia
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title 1
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 title 1
- 229960001183 venetoclax Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1820582.3A GB201820582D0 (en) | 2018-12-18 | 2018-12-18 | CD70 combination therapy |
| GBGB1911007.1A GB201911007D0 (en) | 2019-08-01 | 2019-08-01 | CD70 combination therapy |
| GBGB1917701.3A GB201917701D0 (en) | 2019-12-04 | 2019-12-04 | CD70 Combination therapy |
| PCT/EP2019/085982 WO2020127503A1 (en) | 2018-12-18 | 2019-12-18 | Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105197UA true SG11202105197UA (en) | 2021-07-29 |
Family
ID=69104399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105197UA SG11202105197UA (en) | 2018-12-18 | 2019-12-18 | Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11712468B2 (en) |
| EP (2) | EP3890740B1 (en) |
| JP (1) | JP2022515077A (en) |
| KR (1) | KR20210106428A (en) |
| CN (2) | CN113226317B (en) |
| AU (1) | AU2019409936A1 (en) |
| BR (1) | BR112021011684A2 (en) |
| CA (1) | CA3117282A1 (en) |
| DK (1) | DK3890740T3 (en) |
| ES (1) | ES2941638T3 (en) |
| FI (1) | FI3890740T3 (en) |
| HU (1) | HUE061710T2 (en) |
| IL (1) | IL284015B1 (en) |
| LT (1) | LT3890740T (en) |
| MX (1) | MX2021007350A (en) |
| PL (1) | PL3890740T3 (en) |
| PT (1) | PT3890740T (en) |
| SG (1) | SG11202105197UA (en) |
| TW (1) | TW202038958A (en) |
| UY (1) | UY38511A (en) |
| WO (1) | WO2020127503A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202038958A (en) | 2018-12-18 | 2020-11-01 | 比利時商阿根思公司 | Cd70 combination therapy |
| JP2022537384A (en) * | 2019-06-20 | 2022-08-25 | セルジーン コーポレーション | Azacytidine in combination with venetoclax, gilteritinib, midostaurin, or other compounds to treat leukemia or myelodysplastic syndrome |
| TW202138388A (en) | 2019-12-30 | 2021-10-16 | 美商西根公司 | Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
| CA3188634A1 (en) * | 2020-08-29 | 2022-03-03 | Johannes De Haard | Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor |
| CN117769416A (en) * | 2021-07-21 | 2024-03-26 | 埃默里大学 | BAK activators, pharmaceutical compositions and use in the treatment of cancer |
| WO2023031403A1 (en) * | 2021-09-02 | 2023-03-09 | F. Hoffmann-La Roche Ag | Antibodies for the treatment of aml |
| WO2023081721A1 (en) * | 2021-11-03 | 2023-05-11 | Board Of Regents, The University Of Texas System | Methods relating to treatment of acute myeloid leukemia |
| TW202340177A (en) | 2021-12-30 | 2023-10-16 | 美商拜歐米富士恩股份有限公司 | Pyrazine compounds as inhibitors of flt3 |
| CN114949230A (en) * | 2022-06-13 | 2022-08-30 | 厦门大学附属第一医院 | Combined pharmaceutical composition for preventing and/or treating acute myeloid leukemia and application thereof |
| CN117771177A (en) * | 2023-08-02 | 2024-03-29 | 首都医科大学附属北京儿童医院 | Venezuela self-microemulsifying drug release system and preparation method and application thereof |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| DE19747418C1 (en) | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor protein of the wnt signaling pathway |
| US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
| US20030148321A1 (en) | 2001-08-24 | 2003-08-07 | Iris Pecker | Methods and kits for diagnosing and monitoring hematopoietic cancers |
| AU2002351828A1 (en) | 2001-11-05 | 2003-05-19 | Deutsches Krebsforschungszentrum | Novel genetic markers for leukemias |
| AU2002343109B2 (en) | 2001-11-27 | 2008-06-12 | Ucb Pharma S.A. | Methods for diagnosis and treatment of epithelial-derived cancers, such as colorectal cancers and kidney cancers |
| US7261892B2 (en) | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US8039218B2 (en) | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
| ES2347959T3 (en) | 2003-02-20 | 2010-11-26 | Seattle Genetics, Inc. | ANTI-CD70-FARMACO ANTIBODIES CONJUGATES AND THEIR USE FOR CANCER TREATMENT. |
| US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| AU2005250499B2 (en) | 2004-06-03 | 2011-12-08 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
| US7641903B2 (en) | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| US8337838B2 (en) | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| CA2583208C (en) | 2004-10-15 | 2015-08-25 | Seattle Genetics, Inc. | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| ES2477765T3 (en) | 2005-04-19 | 2014-07-17 | Seattle Genetics, Inc. | Binding agents to humanized anti-cd70 and their uses |
| EP2386854A1 (en) | 2005-04-19 | 2011-11-16 | Prediction Sciences LLC | Diagnostic markers of breast cancer treatment and progression and methods of use thereof |
| WO2007011856A2 (en) | 2005-07-15 | 2007-01-25 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for differential diagnosis of chronic lymphocytic leukemia |
| JP2009509510A (en) | 2005-09-26 | 2009-03-12 | メダレックス インコーポレーティッド | Human monoclonal antibody against CD70 |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| SG172698A1 (en) | 2006-06-12 | 2011-07-28 | Trubion Pharmaceuticals Inc | Single-chain multivalent binding proteins with effector function |
| US8118643B2 (en) | 2006-07-24 | 2012-02-21 | Senda Kensetsu Kabushiki Kaisha | Method of descaling metal wire rod and apparatus therefor |
| PL2099823T5 (en) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Variant target binding agents and uses thereof |
| IN2009KN02404A (en) | 2006-12-14 | 2015-08-07 | Medarex Inc | |
| KR100807069B1 (en) | 2007-09-21 | 2008-02-25 | 고려대학교 산학협력단 | Pharmaceutical composition for treating cancer |
| EP2217223A2 (en) | 2007-11-05 | 2010-08-18 | Novartis AG | Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| WO2010014948A1 (en) | 2008-08-01 | 2010-02-04 | The University Of Utah Research Foundation | Methods of treatment using wnt inhibitors |
| WO2010019921A2 (en) | 2008-08-15 | 2010-02-18 | The Regents Of The University Of California | Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia |
| BRPI0919473A2 (en) | 2008-09-26 | 2017-08-29 | Oncomed Pharm Inc | FRIZZLED BINDING AGENTS AND THEIR USES |
| US8647623B2 (en) | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| DK2464232T3 (en) | 2009-08-10 | 2016-01-04 | Samumed Llc | INDAZOLE INHIBITORS OF THE WNT SIGNAL ROAD AND THERAPEUTIC APPLICATIONS THEREOF |
| US20120178111A1 (en) | 2009-09-23 | 2012-07-12 | Diamandis Eleftherios P | Methods and compositions for the detection of lung cancers |
| KR101773216B1 (en) | 2009-12-29 | 2017-08-31 | 교와 핫꼬 기린 가부시키가이샤 | Anti-cd27 antibody |
| ES2682078T3 (en) | 2010-06-11 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Anti-TIM-3 antibody |
| BR112013012740A2 (en) | 2010-11-23 | 2016-09-13 | Abbvie Inc | salts and crystalline forms of an apoptosis inducing agent |
| DK3020730T3 (en) | 2011-01-19 | 2019-04-15 | Cantargia Ab | ANTI-IL1RAP ANTIBODIES AND THEIR USE FOR TREATMENT OF SOLID TUMORS |
| WO2012123586A1 (en) | 2011-03-16 | 2012-09-20 | arGEN-X BV | Antibodies to cd70 |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| JO3625B1 (en) | 2011-09-22 | 2020-08-27 | Amgen Inc | CD27L Antigen Binding Proteins |
| WO2013093508A2 (en) | 2011-12-22 | 2013-06-27 | Oslo University Hospital Hf | Wnt pathway inhibitors |
| EA030828B1 (en) | 2012-03-15 | 2018-10-31 | Янссен Байотек, Инк. | Human anti-cd27 antibodies, methods and uses |
| US20150086521A1 (en) | 2012-03-21 | 2015-03-26 | Erytech Pharma | Medicament for the Treatment of Acute Myeloid Leukemia (AML) |
| US9801851B2 (en) | 2012-05-23 | 2017-10-31 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias |
| JP6081582B2 (en) | 2012-06-15 | 2017-02-15 | キュアジェニックス インコーポレイテッド | Wnt signaling inhibitors, compositions and compounds as uses thereof |
| WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| WO2014100772A1 (en) | 2012-12-21 | 2014-06-26 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
| KR102215954B1 (en) | 2013-02-14 | 2021-02-15 | 브리스톨-마이어스 스큅 컴퍼니 | Tubulysin compounds, methods of making and use |
| JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
| CN106456749B (en) | 2014-03-11 | 2021-03-30 | 小利兰·斯坦福大学托管委员会 | Anti-sirpa antibodies and bispecific macrophage-enhancing antibodies |
| US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for cd70 and cd3 |
| US20180244792A1 (en) | 2015-09-10 | 2018-08-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
| US11001582B2 (en) | 2016-03-10 | 2021-05-11 | Assia Chemical Industries Ltd. | Solid state forms of Venetoclax and processes for preparation of Venetoclax |
| EP3442584B1 (en) * | 2016-03-15 | 2021-07-28 | Seagen Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| RU2018146513A (en) | 2016-06-09 | 2020-07-09 | Др. Редди'С Лабораторис Лимитед | SOLID FORMS OF VENETO-KLAX AND METHODS FOR PRODUCING A VENETO-KLAX |
| WO2018009444A1 (en) | 2016-07-06 | 2018-01-11 | Concert Pharmaceuticals, Inc. | Deuterated venetoclax |
| CN107648185A (en) | 2016-07-25 | 2018-02-02 | 常州爱诺新睿医药技术有限公司 | A kind of unformed Venetoclax and pharmaceutic adjuvant solid dispersions and preparation method thereof |
| US20190177317A1 (en) | 2016-08-12 | 2019-06-13 | Mylan Laboratories Limited | Process for the preparation of venetoclax |
| WO2018069941A2 (en) | 2016-10-14 | 2018-04-19 | Mylan Laboratories Limited | Polymorphic forms of venetoclax |
| EP3333167A1 (en) | 2016-12-09 | 2018-06-13 | LEK Pharmaceuticals d.d. | Solid forms of venetoclax |
| CZ201769A3 (en) | 2017-02-06 | 2018-08-15 | Zentiva, K.S. | Solid forms of Venetoclax |
| WO2018157803A1 (en) | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | Venetoclax crystal forms and preparation method therefor |
| WO2018167652A1 (en) | 2017-03-13 | 2018-09-20 | Laurus Labs Limited | Process for preparation of amorphous form of venetoclax |
| CN107089981A (en) | 2017-04-24 | 2017-08-25 | 杭州科耀医药科技有限公司 | A kind of inhibitor Venetoclax of BCL 2 synthetic method |
| GB2567613A (en) | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
| GB201800649D0 (en) * | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| TW202038958A (en) | 2018-12-18 | 2020-11-01 | 比利時商阿根思公司 | Cd70 combination therapy |
-
2019
- 2019-12-16 TW TW108146057A patent/TW202038958A/en unknown
- 2019-12-17 UY UY0001038511A patent/UY38511A/en unknown
- 2019-12-18 BR BR112021011684A patent/BR112021011684A2/en unknown
- 2019-12-18 ES ES19831677T patent/ES2941638T3/en active Active
- 2019-12-18 FI FIEP19831677.0T patent/FI3890740T3/en active
- 2019-12-18 EP EP19831677.0A patent/EP3890740B1/en active Active
- 2019-12-18 HU HUE19831677A patent/HUE061710T2/en unknown
- 2019-12-18 AU AU2019409936A patent/AU2019409936A1/en active Pending
- 2019-12-18 MX MX2021007350A patent/MX2021007350A/en unknown
- 2019-12-18 CN CN201980082377.7A patent/CN113226317B/en active Active
- 2019-12-18 PT PT198316770T patent/PT3890740T/en unknown
- 2019-12-18 US US16/719,220 patent/US11712468B2/en active Active
- 2019-12-18 LT LTEPPCT/EP2019/085982T patent/LT3890740T/en unknown
- 2019-12-18 WO PCT/EP2019/085982 patent/WO2020127503A1/en unknown
- 2019-12-18 EP EP23151526.3A patent/EP4218761A1/en active Pending
- 2019-12-18 PL PL19831677.0T patent/PL3890740T3/en unknown
- 2019-12-18 KR KR1020217017438A patent/KR20210106428A/en unknown
- 2019-12-18 CA CA3117282A patent/CA3117282A1/en active Pending
- 2019-12-18 IL IL284015A patent/IL284015B1/en unknown
- 2019-12-18 SG SG11202105197UA patent/SG11202105197UA/en unknown
- 2019-12-18 CN CN202211004780.8A patent/CN115920034A/en active Pending
- 2019-12-18 JP JP2021534948A patent/JP2022515077A/en active Pending
- 2019-12-18 DK DK19831677.0T patent/DK3890740T3/en active
-
2023
- 2023-06-14 US US18/334,582 patent/US20240033353A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3890740T (en) | 2023-05-15 |
| CN113226317B (en) | 2022-08-16 |
| MX2021007350A (en) | 2021-09-21 |
| CN113226317A (en) | 2021-08-06 |
| US20240033353A1 (en) | 2024-02-01 |
| ES2941638T3 (en) | 2023-05-24 |
| HUE061710T2 (en) | 2023-08-28 |
| IL284015B1 (en) | 2024-06-01 |
| WO2020127503A1 (en) | 2020-06-25 |
| DK3890740T3 (en) | 2023-05-08 |
| CN115920034A (en) | 2023-04-07 |
| CA3117282A1 (en) | 2020-06-25 |
| JP2022515077A (en) | 2022-02-17 |
| UY38511A (en) | 2020-07-31 |
| KR20210106428A (en) | 2021-08-30 |
| BR112021011684A2 (en) | 2021-11-30 |
| FI3890740T3 (en) | 2023-05-24 |
| PL3890740T3 (en) | 2023-07-24 |
| AU2019409936A1 (en) | 2021-05-27 |
| EP4218761A1 (en) | 2023-08-02 |
| US20200222532A1 (en) | 2020-07-16 |
| IL284015A (en) | 2021-08-31 |
| US11712468B2 (en) | 2023-08-01 |
| EP3890740A1 (en) | 2021-10-13 |
| LT3890740T (en) | 2023-03-27 |
| TW202038958A (en) | 2020-11-01 |
| EP3890740B1 (en) | 2023-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284015A (en) | Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia | |
| IL277435A (en) | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma | |
| LT3704108T (en) | Irak4 inhibitor in combination with a bcl-2 inhibitor for use in treating cancer | |
| EP3436014A4 (en) | Combination therapy for the treatment of acute myeloid leukemia | |
| ZA202204657B (en) | Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia | |
| IL275949A (en) | Combination therapy for treating or preventing cancer | |
| SG11202006893WA (en) | Disrupting the linc complex for treating laminopathy | |
| PH12018501943A1 (en) | Pharmaceutical compositions for the treatment of cancer | |
| IL288864A (en) | Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors | |
| IL288178A (en) | Gmci and ddri combination therapy for treating cancer | |
| IL286680A (en) | Medicament for treating cancer | |
| IL281670A (en) | Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer | |
| IL276073A (en) | Combination therapy for treating or preventing cancer | |
| IL276074A (en) | Combination therapy for treating or preventing cancer | |
| IL275860A (en) | Combination therapy for treating or preventing cancer | |
| GB201808636D0 (en) | Combination therapy for treating or preventing cancer | |
| GB201808628D0 (en) | Combination therapy for treating or preventing cancer | |
| GB201808631D0 (en) | Combination therapy for treating or preventing cancer | |
| GB201808632D0 (en) | Combination therapy for treating or preventing cancer | |
| EP3886833A4 (en) | Therapeutic methods and compositions for treating acute myeloid leukemia using devimistat | |
| GB201806572D0 (en) | Combination therapy for treating or preventing cancer | |
| GB201805941D0 (en) | Combination therapy for treating or preventing cancer | |
| GB201801502D0 (en) | Combination therapy for treating or preventing cancer | |
| GB201800927D0 (en) | Combination therapy for treating or preventing cancer | |
| GB201917701D0 (en) | CD70 Combination therapy |